Q1 2026 · 13F-HR
Medicxi Ventures Management (Jersey) Ltdholdings as filed
Filed 2026-04-21 · accession 0001193125-26-166701
$981.8M
Reported value
4
Positions
2026-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $792.9M | 80.8% | 19,963,157 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $85.6M | 8.72% | 2,674,182 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS INC | $82.9M | 8.45% | 7,464,572 | Common | SOLE |
| 05153U107 | AURA | AURA BIOSCIENCES INC | $20.3M | 2.07% | 3,039,892 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.